Ovarian cancer diagnostics company, Cleo Diagnostics Limited (ASX:COV) is pleased to provide the market with an update on activities in the June 2024 quarter as it develops its simple and accurate blood test for the early detection of ovarian cancer.

Ovarian cancer diagnostics company, Cleo Diagnostics Limited (ASX:COV) (CLEO, or the Company) is pleased to announce progress in its regulatory strategy for its first commercial product, the pre-surgical triage test.

Ovarian cancer diagnostics company, Cleo Diagnostics Limited (ASX:COV) is pleased to announce the publication of a milestone article on its blood test for the accurate and early detection of ovarian cancer.